Trial results

Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes

NCT02503943 on ClinicalTrials.gov · last registry update 2015-07-21

90 participants. Its estimated completion date, September 2016, has passed with no update to the record. Primary outcome, as filed: Blood Pressure change. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

UNKNOWN

Phase

P4

Drug

liraglutide

Saxenda, Victoza, Xultophy

Sponsor

Third Affiliated Hospital of Third Military Medical University

Sponsor type

Other

Enrollment

90

Started

2015-05

Primary completion

2016-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Blood Pressure change

Conditions studied

Type 2 Diabetes · Overweight · Obesity · Masked Hypertension

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.